Rybelsus vs Ozempic Tablets: What the 2026 Name Change Means for Oral Semaglutide

On 4 February 2026 the FDA approved semaglutide tablets under the Ozempic name at 1.5 mg, 4 mg and 9 mg, and approved Ozempic as the brand name for oral semaglutide in the United States in place of Rybelsus. The tablets reached US pharmacies on 4 May 2026. Rybelsus, which had been the only oral GLP-1 receptor agonist on the US market since 2019, is being withdrawn from the United States while continuing to be sold in the rest of the world.

That change created a specific and avoidable problem. Two oral semaglutide products now exist, both from Novo Nordisk, both containing the same molecule, and their strengths do not line up. Somebody moving from a 14 mg tablet to a 9 mg tablet has not had their dose reduced. Somebody who assumes 4 mg is a step down from 7 mg has misread the situation entirely. This guide sets out what the two products are, how the strengths correspond, and exactly what the prescribing information says about moving between them.

What actually changed

The active ingredient did not change. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, and it works the same way in both tablets. What changed is the formulation and the labelled strengths.

Oral semaglutide has always faced a delivery problem. Semaglutide is a peptide, and peptides are destroyed by stomach acid and digestive enzymes. Rybelsus solved this by co-formulating semaglutide with an absorption enhancer called SNAC, which raises local pH in a small area of the stomach lining and lets a fraction of the dose cross intact. It works, but the absorbed fraction is small and highly sensitive to conditions in the stomach.

The reformulated tablet, developed under the internal designation R2, improves that absorption. Because more of each milligram is absorbed, lower labelled strengths produce the same blood levels. That is the whole reason 4 mg of the new tablet replaces 7 mg of the old one. The dose in your body is broadly the same. The number printed on the tablet is not.

The strengths do not convert milligram for milligram

This is the single most important line in the new prescribing information, and it is stated in the highlights section rather than buried: the two tablet products are not substitutable on a milligram-to-milligram basis. Here is how the strengths correspond.

Phase	Rybelsus	Ozempic tablets
Initiation, days 1 to 30	3 mg once daily	1.5 mg once daily
Escalation, days 31 to 60	7 mg once daily	4 mg once daily
Maintenance, day 61 onward	7 mg once daily	4 mg once daily
Higher maintenance if more glucose lowering is needed	14 mg once daily	9 mg once daily

Read the table as three pairs, not six numbers. Rybelsus 3 mg and Ozempic tablets 1.5 mg are both the starting dose, and the label is explicit that neither is effective for glycaemic control on its own. They exist only to let the gut adjust before a therapeutic dose arrives. Rybelsus 7 mg pairs with Ozempic tablets 4 mg. Rybelsus 14 mg pairs with Ozempic tablets 9 mg.

The practical failure mode is a person who has been stable on 14 mg for two years, receives a 9 mg tablet at the pharmacy counter, concludes their prescriber has cut the dose by a third, and either doubles up or stops. Neither reaction is warranted. Nine milligrams of the new tablet is the top maintenance dose.

The rules on switching between the two tablets

The label sets out three conditions, and they are worth reading in order.

• Do not switch during the initiation phase. The first 30 days on either product are a fixed block. Switching mid-block restarts the tolerance clock and raises the chance of gastrointestinal symptoms.
• After 30 days, a switch is permitted between the escalation and maintenance strengths using the pairings in the table above.
• Start the new product the day after stopping the old one. There is no washout gap and no overlap. Last tablet of the old product on one morning, first tablet of the new product the next.

The absence of a washout period follows from the pharmacology. Semaglutide has a half life of about a week, so a gap of several days would not clear the drug anyway, and a genuine break would only mean an unnecessary dip in exposure.

Switching from Ozempic injection to a tablet

This is a separate manoeuvre with its own rule, and the label is narrow about who qualifies. Only patients taking the 0.5 mg dose of Ozempic injection are covered. One week after the last 0.5 mg injection, oral dosing begins at either 7 mg or 14 mg of Rybelsus, or 4 mg or 9 mg of Ozempic tablets.

Two things stand out. First, the one week gap exists because the last injection is still being absorbed and cleared, and starting an oral dose immediately would stack exposures. Second, there is no initiation phase on the way in from an injection. Somebody already on injected semaglutide has a gut that has adapted, so the 3 mg or 1.5 mg on-ramp is skipped.

The label does not give a conversion for people on 1 mg or 2 mg injections moving to tablets. That is a prescriber decision made outside the labelled instructions, not something to work out from a dose chart.

Why Rybelsus still exists outside the United States

Novo Nordisk has confirmed that Rybelsus continues to be marketed outside the US. The rebrand and the reformulation are a United States regulatory event, not a global withdrawal. In Australia, the United Kingdom, Canada, India and most other markets, oral semaglutide remains Rybelsus at 3 mg, 7 mg and 14 mg.

That matters for anyone sourcing internationally. The Rybelsus 3mg, Rybelsus 7mg and Rybelsus 14mg tablets we stock are the Novo Nordisk India product, which is the same three-strength Rybelsus range still sold across most of the world. A prescription written for Rybelsus 14 mg is filled with a Rybelsus 14 mg tablet, with no conversion arithmetic involved.

The point worth stating plainly is that the confusion runs one direction. Somebody in the United States now has to translate their old Rybelsus dose into an Ozempic tablet strength. Somebody filling a Rybelsus prescription against international supply does not.

What did not change at all

The administration rules are identical for both tablets, and they are stricter than almost any other oral medicine. Because SNAC-assisted absorption depends on conditions in an empty stomach, the label is unusually prescriptive:

• Take the tablet on an empty stomach in the morning, immediately after waking.
• Take it with no more than four ounces of plain water. Not coffee, not juice, not tea.
• Swallow the tablet whole. Do not split, crush, chew or dissolve it.
• Wait at least 30 minutes before food, any other drink, or any other oral medicine.
• One tablet per day, no more. If a dose is missed, skip it and take the next one the following day.

Our oral semaglutide dosing guide explains the pharmacokinetics behind each of these rules and what actually happens to absorption when they are broken.

The boxed warning is also unchanged. Both tablets carry the same warning about thyroid C-cell tumours seen in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Contraindication also applies after any prior serious hypersensitivity reaction to semaglutide or the tablet excipients.

The safety data behind both products comes from the same Rybelsus trial programme. The FDA approved the reformulation on the basis of a bioequivalence study plus a clinical trial, not a fresh phase 3 programme, which is why the adverse reaction tables in the new label still describe patients who took 7 mg and 14 mg. We cover those figures dose by dose in our guide to semaglutide side effects by dose.

Where the injectable products sit in all this

The rebrand has folded oral and injectable semaglutide under one name in the United States, which makes it easy to lose track of which product does what. Four distinct things now exist:

• Ozempic injection, once weekly, for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes at high risk.
• Ozempic tablets, once daily at 1.5, 4 or 9 mg, for the same indications, launched in the US in May 2026.
• Wegovy injection, once weekly at up to 2.4 mg, for chronic weight management under prescriber supervision, with a further indication in noncirrhotic MASH with moderate to advanced liver fibrosis.
• Wegovy 25 mg tablet, approved in December 2025 as the first oral GLP-1 receptor agonist indicated for chronic weight management.

The injectable side of our range includes the Wegovy 0.25mg FlexTouch pen through to the Wegovy 2.40mg pen, along with generic semaglutide pens including Sematrinity 2mg, Sematrinity 4mg and the Noveltreat pre-filled pen range from Sun Pharmaceutical.

What this means if you are holding a prescription right now

Three situations cover most people.

You are in the United States on Rybelsus. Novo Nordisk has advised patients to continue their current medicine as directed and to discuss transitioning with their prescriber. The transition is not urgent and it is not automatic. When it happens, use the pairings above and expect a lower printed number for the same effective dose.

You are outside the United States. Nothing changes. Rybelsus 3 mg, 7 mg and 14 mg remain the marketed strengths and prescriptions written against them are filled as written.

You are sourcing internationally against a US prescription. Check which product the prescription names. A prescription for Ozempic tablets 9 mg and a prescription for Rybelsus 14 mg describe the same treatment intensity, but they are different products, and only one of them is available outside the United States.

A further change is still pending. Novo Nordisk has filed a supplemental application for a 25 mg Ozempic tablet for type 2 diabetes, with an FDA decision expected by the end of 2026. If approved, the oral range in the United States extends further above the current 9 mg ceiling, and the gap between US and international oral semaglutide strengths widens again.

The short version

Same molecule, better absorbed, lower numbers on the tablet. Rybelsus 3 mg maps to Ozempic tablets 1.5 mg, 7 mg maps to 4 mg, and 14 mg maps to 9 mg. Do not switch inside the first 30 days, start the new product the day after stopping the old one, and treat a lower milligram figure as a formulation change rather than a dose reduction. Everything else, from the empty stomach rule to the boxed warning, carries over unchanged.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Semaglutide requires a prescription in the United States, United Kingdom, Canada and Australia. Do not start, stop, switch or adjust semaglutide without speaking to your prescriber. Dose conversion between products, and any decision about which product suits you, depends on your glycaemic control, kidney function, other medicines and medical history, which only a clinician who knows your case can weigh.

References

• FDA-approved prescribing information for RYBELSUS and OZEMPIC (semaglutide) tablets, Dosage and Administration sections 2.1 to 2.4, Contraindications, and Boxed Warning.
• FDA-approved prescribing information for RYBELSUS (semaglutide) tablets, reference ID 5679328, Adverse Reactions section 6.1.
• Novo Nordisk news release, 1 May 2026: Ozempic tablets 1.5 mg, 4 mg and 9 mg available in the US from 4 May 2026.
• Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. PubMed PMID: 31186300.
• Smits MM, Van Raalte DH. Safety of Semaglutide. PubMed PMID: 34305810.